MODULATION OF ANTIBODY-MEDIATED GLOMERULAR INJURY IN-VIVO BY INTERLEUKIN-6

We have shown previously that pretreatment with small doses of bacteri al lipopolysaccharide (LPS), human recombinant interleukin-1beta (hrIL -1beta) and human recombinant tumor necrosis factor-alpha (hrTNF) incr ease injury in the heterologous phase of nephrotoxic nephritis (NTN). All three pretreatments induce synthesis of interleukin-6 (IL-6) which in some systems down-regulates synthesis of IL-1 and TNF. We have now investigated the influence of IL-6 on injury in both heterologous and autologous phases of NTN in rats. Injection of hrIL-6 in doses suffic ient to induce hepatic synthesis of acute phase proteins (assessed by plasma alpha2-macroglobulin concentration) had no effect on glomerular injury in the heterologous phase of NTN (albuminuria in NTAb alone 9 +/- 6; LPS/NTAb 34 +/- 10 and IL-6/NTAb 2 +/- 1 mg/24 hr, P < 0.001, W ilcoxon test). In contrast, IL-6 pretreatment partially abrogated the effect of LPS on albumin excretion (NTAb 4 +/- 2; LPS/NTAb 85 +/- 11 a nd IL-6/LPS/NTAb 32 +/- 6 mg/24 hr, P < 0.002), percentage of glomerul ar capillary thrombi (3 +/- 1%; 39 +/- 8%; and 6 +/- 1%, P < 0.001) an d glomerular neutrophil infiltrate (29 +/- 3; 58 +/- 5; and 34 +/- 2 n eutrophils/50 glomeruli in section, P < 0.001, respectively) at 24 hou rs. The effect of IL-6 was also evident four hours after induction of nephritis and was associated with a marked reduction in glomerular con centration of mRNA for IL-1beta and TNF, without change in that of tub ulin. Serum TNF concentrations were also significantly reduced at four hours in IL-6 treated rats. Glomerular macrophage counts were unaffec ted by the treatment of IL-6 at four (53 +/- 1; 55 +/- 3 and 64 +/- 7) or 24 hours (201 +/- 12; 198 +/- 9 and 202 +/- 9, respectively). A si ngle injection of IL-6 also decreased albumin excretion by 42% in the autologous phase of NTN, and reduced the prevalence of glomerular capi llary thrombosis by 68%. These results show that IL-6 has significant anti-inflammatory properties in this model of antibody mediated injury in vivo.